• • 

    

    Alfredo L. Falcone, MD

    Peer

  • 

    

    Sebastian Stintzing, MD

    Peer

  • 

    

    Tianshu Liu, MD

    Peer

  3

  

  RestartResume

  RestartResume

  Considerações Clínicas na Sequenciação do Tratamento do CCRM

• • 

    

    Kenneth C. Anderson, MD

    Peer

  • 

    

    Philippe Moreau, MD

    Peer

  7

  

  RestartResume

  RestartResume

  Real-World Treatment Effectiveness Compared with Clinical Trial Efficacy in M...

• • 

    

    Alfredo L. Falcone, MD

    Peer

  • 

    

    Sebastian Stintzing, MD

    Peer

  • 

    

    Tianshu Liu, MD

    Peer

  6

  

  RestartResume

  RestartResume

  Clinical Considerations in Treatment Sequencing for mCRC

• • 

    

    Scott Kopetz, MD, PhD, FACP

    Peer

  • 

    

    Alberto Sobrero, MD

    Peer

  • 

    

    Rui-Hua Xu, MD

    Peer

  15

  

  RestartResume

  RestartResume

  Mejorar la práctica clínica en el tratamiento del CCRm: énfasis en la lateral...

• • 

    

    Scott Kopetz, MD, PhD, FACP

    Peer

  • 

    

    Alberto Sobrero, MD

    Peer

  • 

    

    Rui-Hua Xu, MD

    Peer

  15

  

  RestartResume

  RestartResume

  Melhorar a Prática Clínica na Gestão do mCRC: Ênfase no Lado do Tumor

• • 

    

    Scott Kopetz, MD, PhD, FACP

    Peer

  • 

    

    Alberto Sobrero, MD

    Peer

  • 

    

    Rui-Hua Xu, MD

    Peer

  19

  

  RestartResume

  RestartResume

  Improving Clinical Practice in Management of mCRC: A Focus on Tumor Sidedness

Featured

• • 

    

    Scott Kopetz, MD, PhD, FACP

    Peer

  • 

    

    Alberto Sobrero, MD

    Peer

  • 

    

    Rui-Hua Xu, MD

    Peer

  19

  

  RestartResume

  RestartResume

  Improving Clinical Practice in Management of mCRC: A Focus on Tumor Sidedness

• • 

    

    Timothy A. McCarthy, MD

    Peer

  14

  

  RestartResume

  RestartResume

  Precision Oncology: Incorporating Next Generation Sequencing (NGS) in NSCLC

• • 

    

    Edward S. Kim, MD

    Peer

  3

  

  RestartResume

  RestartResume

  The Value of Multidisciplinary Teams in NSCLC Care Plans

• 4

  

  RestartResume

  RestartResume

  Best Practices for Existing Epidermal Growth Factor Receptor (EGFR) Inhibitor...

• • 

    

    Athanassios Argiris, MD, PhD, FACP

    Peer

  2

  

  RestartResume

  RestartResume

  Role of Immunotherapy in Head & Neck Cancer
• 3

  

  RestartResume

  RestartResume

  Novel Therapies for Head & Neck Cancer
• 2

  

  RestartResume

  RestartResume

  Management of Recurrent Squamous Cell Carcinoma of the Head & Neck

• • 

    

    Tanguy Seiwert, MD

    Peer

  4

  

  RestartResume

  RestartResume

  Targeted Therapy for Head & Neck Cancer

• • 

    

    Makoto Tahara

    Peer

  6

  

  RestartResume

  RestartResume

  Patient Case Study: Role of Cetuximab in treatment of SCC Head and Neck Cance...
• 10

  

  RestartResume

  RestartResume

  Interview with Makoto Tahara, MD, PhD | Japan
• 10

  

  RestartResume

  RestartResume

  Interview with Jan B. Vermorken, MD, PhD | Belgium